Health Care Microfluidics Market to Grow to Nearly $4 Billion in 2020
Driven by in-vitro diagnostics and robust demand in developing nations, microfluidics in health care will grow at 13% annually through 2020, Lux Research says
BOSTON, MA – July 21, 2015 – Microfluidics can offer portable, cheap, single-use devices that replace centralized laboratory equipment in health care facilities, and open new point-of-care (POC) diagnostic opportunities. As the technology advances and medicine grows more personalized, the overall health care market for microfluidics will swell to nearly $4 billion in 2020, growing at a compound annual growth rate (CAGR) of 13%, according to Lux Research.
“Microfluidics has numerous potential applications in health care, including drug discovery, formulation, and delivery, as well as life sciences research,” said Milos Todorovic, Lux Research Analyst and lead author of the report titled, “Health Care Microfluidics Value Chain: A Story of Growing Pains.”
“However, POC diagnostics is going to be the biggest opportunity for microfluidics, with markets in the developing world providing the greatest growth,” he added.
Lux Research analysts evaluated the opportunities for microfluidics in health care. Among their findings:
- Chip developers and device integrator will dominate. The typical value chain for microfluidics remains undifferentiated, offering opportunities for vertical integration. Lux Research expects two types of companies to eventually dominate the microfluidics value chain – chip developers or manufacturers like miniFAB and Sony DADC, and device integrators like Agilent and Fluidigm.
- Device integrators will capture 50% of profits. End device integrators that bring together device design, manufacturing and microfluidics devices will capture nearly 50% of the profit pool. Material suppliers will account for about 24%, while sensing solutions, manufacturing, and design services share the rest.
- Point-of-care market to triple to nearly $1 billion. POC diagnostics will grow at 20% CAGR, driven by low-cost, portable diagnostics solutions for applications in infectious diseases and lifestyle-related conditions. Drug discovery and formulation will remain a leading use, with $1.2 billion in 2020.
The report, titled “Health Care Microfluidics Value Chain: A Story of Growing Pains,” is part of the Lux Research BioElectronics Intelligence service.